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(see METHODS, Supplementary Table 1 and Supplementary Fig. 1 ). We estimated copy number 170 (CN) from five data types: single nucleotide polymorphism (SNP) array, whole-exome sequencing 171 (WES), low-pass whole-genome sequencing (WGS), RNA sequencing (RNA-Seq) and gene 172 expression array data, yielding 1548 tumor datasets including samples assayed on multiple 173 platforms. Paired-normal DNA and in some cases, paired normal RNA, were also obtained to 174 calibrate WES and RNA-Seq tumor samples. To estimate the CNA profiles for the different data 175 types, we used tools including ASCAT for SNP arrays 35 , Sequenza for tumor-normal WES 36 , 176 qDNAseq 37 and ASCAT for WGS and e-karyotyping 38 for gene expression (RNA-Seq and gene 177 expression array) data (see METHODS). Copy number segments for each sample were filtered 178 for measurement noise, median-centered, and intersected with gene coordinates (see 179 METHODS, Supplementary Data 1).
180
The combined PDX data represent 16 broad tumor types (see METHODS), with 64% 181 (n=324) of the models having their corresponding patient tumors assayed and another 64% 182 (n=328) having multiple PDX samples of either varying passages (ranging from P0 -P21) or 183 varying lineages from propagation into distinct mice ( Fig. 1a , Supplementary Table 2 ). The 184 distributions of PT and PDX samples across different tumor types, passages, and assay platforms 185 ( Fig. 1b, Supplementary Fig. 2-12) show the wide spectrum of this combined dataset, which is 186 the most comprehensive copy number profiling of PDXs compiled to date. Additionally, our data 187 include 7 patients with multiple tumors collected either from different relapse time points or 188 different metastatic sites, resulting in multiple PDX models derived from a single patient.
190

Comparison of CNA profiles from SNP array, WES and gene expression data 191
To compare the CNA profiles from different platforms in a controlled fashion, we assembled a 192 benchmarking dataset with matched measurements across multiple platforms ( Supplementary   193   Table 3 , Supplementary Fig. 13 -17 ). Copy number calling has been reported to be noisy for 194 several data types 39, 40 , and we observed that quantitative comparisons between CNA profiles are 195 sensitive to: (1) the thresholds and baselines used to define gains and losses, (2) the dynamic 196 range of copy number values from each platform, and (3) the differential impacts of normal cell 197 contamination for different measurements. To control for such systematic biases, we assessed 
277
For all DNA-based platforms we observed strong concordance between matched PT-PDX 278 and PDX-PDX pairs, significantly higher than between different models from the same tumor type 279 and the same center (p < 2.2e -16 ) ( Fig. 3a -c, correlation heatmaps in Supplementary Fig. 27 -280 63). We observed no significant difference in the correlation values between PT-PDX and PDX-281 PDX pairs for SNP array data (median correlation PT-PDX = 0.950, PDX-PDX = 0.964; p > 0.05), 282 though there were small but statistically significant shifts for WES (PT-PDX = 0.874, PDX-PDX = 283 0.936; p = 2.31e -16 ) and WGS data (PT-PDX = 0.914, PDX-PDX = 0.931; p = 0.000299). PT 284 samples have a smaller CNA range than their derived PDXs (median ratio PT/PDX / PDX/PDX: 285 0.832/0.982, p = 0.000120 for SNP; 0.626/0.996, p < 2.2e -16 for WES; 0.667/1.00, p < 2.2e -16 for 286 WGS; Supplementary Fig. 64b and 65 ), which can be attributed to stromal DNA in PT samples 287 "diluting" the CNA signal. In PDXs, the human stromal DNA is reduced 9,15 . The minimal effect for 288 SNP array data confirm this interpretation -human stromal DNA contributions to CNA estimates 289 can be removed from SNP arrays based on allele frequencies of germline heterozygous sites, 290 while such contributions to WES and WGS have higher uncertainties.
291
We also performed intra-model comparisons using RNA-based approaches, but the 292 Pearson correlations between pairs of samples did not clearly reproduce the Pearson correlations 293 from DNA-based platforms for those same sample pairs ( Supplementary Fig. 66a ). To clarify this, 294 we considered just the highly-correlated cases (>0.8 for SNU-JAX Gastric cancer WES, >0.9 for 295 SIBS HCC SNP). We observed that the correlation values for the corresponding RNA-based 296 methods were lower and had higher variance (p < 0.05, Supplementary Fig. 66b ). In particular, 297 the tumor-median normalization for expression data resulted in significant differences from DNA-298 based methods.
300
Late PDX passages maintain CNA profiles similar to early passages. Next, we asked if there 301 is any systematic evolution of copy number during engraftment and passaging. Mouse 302 environment-driven evolution, if present, should reduce CN correlations relative to early samples, 303 such as the primary tumor or first engraftment (P0). However, we observed no apparent effect 304 during passaging on the SNP, WES, or WGS platforms ( Fig. 3d -f , Supplementary Fig. 67 ). For 305 example, the SNP data showed no significant difference between passages ( Fig. 3d and 306 Supplementary Fig. 67a ). For those models having very late passages (14 breast cancer models, 307 P18 to P21), there was a small but statistically significant correlation decrease compared to 308 models with earlier passages (p < 8.98e -05 , Supplementary Fig. 68 ), indicating some copy number 309 changes can occur over long-term passaging ( Supplementary Fig. 38 ). However even at these 310 late passages, the correlations to early passages remained high (median = 0.896). In any given 311 comparison, only a small proportion of the genes were affected by copy number changes (median: 312 2.72%, range: 1.03% -11.9%). Genes that are deleted and subsequently gained in the later 313 passages (top left quadrant of regression plots, Supplementary Fig. 69 ) suggest selection of 314 preexisting minor clones as the key mechanism in these regions. For WES and WGS data, more 315 variability in the correlations can be observed ( Fig. 3e and f, Supplementary Fig. 66b and c), likely 316 due to a few samples having more stromal contamination or low aberration levels (Supplementary 317 Fig. 64b and 65 ). However, the lack of downward trend over passaging was also apparent in 318 these sets. 319 320 PDX copy number profiles trace lineages. We next compared the similarity of engrafted PDXs 321 of the same model with the same passage number (i.e. all P0s, all P1s, all P2s, etc.). Surprisingly,
322
we discovered that these fragments were not more similar than PDXs from different passage 323 numbers ( Fig. 3d -e and Supplementary Fig. 66b , IQR of correlation coefficient for same-324 passages/different-passages: 0.0700/0.0619 for SNP and 0.103/0.0979 for WES). To further this 325 analysis, we defined, for JAX SNP array and PDMR WES datasets, samples within a lineage as 326 those differing only by consecutive serial passages, while we defined lineages as split when a 327 tumor was divided and propagated into multiple mice ( Fig. 3g ). For the EurOPDX CRC and BRCA
328
WGS datasets, such lineage splitting was due only to cases with initial engraftment of different 329 fragments of the PT, i.e., PDX samples of different passages were considered as different 330 lineages if they originate from different PT fragments. We observed lower correlation between 331 PDX samples from different lineages compared to within a lineage ( Fig. 3h , p = 0.0233 for SNP, 332 p = 0.00119 for WES, p = 0.000232 for WGS), despite a majority of these pairwise comparisons 
338
We next asked if the phylogenetic distance between samples could explain the observed 339 shifts in the correlations. These distance relationships are clearest for the CRC and BRCA WGS 340 sets because these models have only one lineage split occurring at the engraftment stage. We 341 compared correlation as a function of phylogenetic distance within a lineage, which in this 342 phylogeny is simply equal to the difference in passage number between the two samples.
343
Increase in passage difference did not consistently reduce the correlation between samples 344 ( Supplementary Fig. 70 ). This suggests that lineage-splitting is often responsible for deviations in 345 CNAs between samples, and that copy number evolution during passaging mainly arises from 346 evolved spatial heterogeneity 27 .
348
Genes with copy number alterations acquired during engraftment and passaging show no 349 preference for cancer or treatment-related functions.
350
Next, we investigated which genes tend to undergo copy number changes. Genes with changes 351 during engraftment or during passaging were identified based on a residual threshold with respect 352 to the improved linear regression 48 (see METHODS, Supplementary Fig. 26 358 genes with frequent amplifications or deletions in the Cancer Gene Census 52 (Cosmic version 359 89). We calculated the proportion of altered genes for sample pairs from each model across all 360 platforms and tumor types. In agreement with the high maintenance of CNA profiles described 361 above, we found the proportion of altered protein-coding genes to be low (median/IQR: 1.90%/ 362 4.11% PT-PDX, 1.25%/ 3.60% PDX-PDX pairs, Fig. 4a ). Only 8.78% of PT-PDX pairs and 4.53%
363
PDX-PDX pairs showed >10% of their protein-coding genes altered. We observed no significant 364 increase (p < 0.1) in alterations among any of the cancer gene sets compared to the background 365 of all protein-coding genes, for either the PT-PDX or PDX-PDX comparisons. This provides 366 evidence that there is no systematic selection for CNAs in oncogenic or treatment-related 367 pathways during engraftment or passaging. We next considered tumor-type-specific effects,
368
focusing on types with larger numbers of models to ensure statistical power (breast cancer, 369 colorectal cancer, lung adenocarcinoma and lung squamous cell carcinoma). Genomic Identification of Significant Targets in Cancer (GISTIC) 53,54 analysis of TCGA tumors has 371 previously identified significantly altered genomic driver regions which can be used to differentiate 372 tumor types and subtypes [55] [56] [57] [58] . We observed no significant increase in alterations in tumor-type-373 specific GISTIC gene sets compared to the background (p < 0.1) for either PT-PDX or PDX-PDX 374 comparisons ( Fig. 4b ).
376
Low recurrence of altered genes across models. We tested if any particular genes often 377 recurred in CNAs across models. Using a stringent CNA threshold (|log2(CN ratio) change| > 1.0 378 with respect to linear regression model) to distinguish genes with possible functional impact (see 379 METHODS), we observed a very low recurrent frequency ( Fig. 4c ), with only 12 and 2 genes 380 recurring at > 5% frequency for PT-PDX and PDX-PDX comparisons, respectively 381 ( Supplementary Table 4 ). No gene had a recurrence frequency higher than 8.96%. We observed 382 that all these recurrent genes overlapped models in which one sample displayed an unusually 383 large gain or loss (|log2 (CN ratio)| > 1.5). This suggests that these regions may be subject to 384 more noise in the CNA estimation procedure at these loci ( Supplementary Fig. 71 ). None of these 385 recurrent genes overlapped cancer-or treatment-related gene sets, nor did they intersect genes 386 (n=3) reported by Ben-David et al. 26 to have mouse-induced copy number changes associated 387 with drug response in the CCLE 59,60 database. We further queried from CCLE data whether any 388 of these recurrent genes showed evidence for copy number-related drug response (see 389 METHODS, Supplementary Table 5 ). For the 6 genes with sufficient data available, we found no 390 association between copy number and drug response mediated by gene expression (q-value < 391 1). Table 6 ). As expected, CRCs and BRCAs generated 403 different patterns of significant CNAs, with each similar to the GISTIC patterns in their respective TCGA series ( Supplementary Fig. 72 ). However, within each tumour type GISTIC profiles of the 405 PT, PDX-early, and PDX-late cohorts were virtually indistinguishable ( 
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Absence of CNA shifts in 130 WGS patient tumour, early passage PDX and late passage
407
To clarify these behaviors, we carried out gene-level analysis, where each gene was 408 attributed the GISTIC score (G-score) of the respective segment ( Supplementary Table 7 ). In both 409 the CRC and BRCA cohorts, gene-level G-scores of the PTs were highly correlated with the 410 respective PDX-early and PDX-late cohorts ( Fig. 5b and 
417
Lack of CNA-based functional shifts in trios confirms the absence of mouse-specific 418 evolution. We then considered the possibility of systematic copy number evolution at the pathway 419 level in these triplets. To evaluate this, we performed Gene Set Enrichment Analysis (GSEA) 61,62 420 using G-scores to rank genes in each cohort (See METHODS). Consistent with the known 421 recurrence of cancer CNAs at driver genes, multiple gene sets displayed significant enrichment 422 in individual cohorts. To avoid spurious apparent enrichment for sets of genes with adjacent 423 chromosomal location, we implemented an additional filter based on G-score significance (see 424 METHODS and Supplementary Table 8 ). After applying the Normalized Enrichment Score (NES),
425
FDR q-value and G-score filters, 49 gene sets were found to be significant in at least one of the 426 three CRC cohorts, and 89 gene sets in at least one of the three BRCA cohorts (Supplementary 427   Table 9 ). Importantly, control gene sets composed of GISTIC hits identified in TCGA CRC and 428 BRCA datasets were all significant, confirming that the WGS cohorts used here correctly 429 recapitulate the major CNA features of these two cancer types.
430
However, differences associated with PDX engraftment and passage were negligible. For 431 both CRC and BRCA, the NES profiles for the ~8000 gene sets of PTs were highly correlated 432 with the respective PDX-early and PDX-late cohorts ( Fig. 5d and 
439
CNA evolution across PDXs is no greater than variation in patient multi-region samples 440
As a reference for the treatment relevance of PDX-specific evolution, we compared to levels of 441 copy number variation in multi-region samples of patient tumors. For this we used copy number 442 data from multi-region sampling of non-small-cell lung cancer (92 patient tumors, 295 multi-region 443 samples) from the TRACERx Consortium 31 , performing analogous CNA correlation and gene 444 analyses (|residual| > 0.5) between multi-region pairs ( Supplementary Fig. 73 ). We observed no 445 significant differences in correlation (p > 0.05) between patient multi-region and lung cancer PT-
446
PDX pairs, while PDX-PDX pairs in fact showed significantly better correlation than the multi- Supplementary Fig. 3 , 4 and 7). We observed no significant difference between the 456 CNA evolution during engraftment and passaging compared to the intra-patient samples ( Fig. 6c ).
457
CNA profiles for these samples are shown visually in Fig. 6d .
459
DISCUSSION
460
Here we have investigated the evolutionary stability of patient-derived xenografts, an important 461 model system for which there have been prior reports of mouse-induced copy number evolution.
462
To better address this, we assembled the largest collection of CNA profiles of PDX models 463 reported to date, comprising over 1500 datasets from PDX samples of multiple passages and 464 their originating patient tumors from more than 500 PDX models across a variety of tumor types.
465
Our analysis demonstrated the reliability of copy number estimation by DNA-based 466 measurements over RNA-based inferences, which are substantially inferior in terms of resolution 467 and accuracy. The importance of DNA measurements is supported by the inconsistent 468 conclusions by two independent studies on the same PDX expression array datasets by Gao et 469 al. 19 Ben-David et al. 26, 63 concluded that drastic copy number changes, driven by mouse-specific 470 selection, often occur within a few passages. On the other hand, Mer et al. 64 reported high similarity between passages of the same PDX model based on direct correlations of gene 472 expression, consistent with our findings in large, independent DNA-based datasets.
473
To understand this, we note that the CN shifts inferred by 
492
The studies we have presented here take into account the above issues by use of DNA 493 data, as well as by assessing copy number changes by pairwise correlation/residual analysis to 494 control for systematic biases, and they overall confirm the high retention of CNA profiles from 495 PDX engraftment to passaging. We do observe larger deviations between PT-PDX than in PDX-
496
PDX comparisons, though this is likely due to dilution of PT signal by human stromal cells.
497
Interestingly, we found that a major contributor to the differences between PDX samples is 498 lineage-specific drift associated with splitting of tumors into fragments during PDX propagation.
499
This spatial evolution within tumors appears to affect sample comparisons more than time or the 500 number of passages.
501
A challenge for evaluating any model system is that there is no clear threshold for genomic 502 change that determines whether the model will still reflect patient response. Genetic variation 503 among multi-region samples within a patient can shed light on this point, since the goal of a 504 successful treatment would be to eradicate all of the multiple regions of the tumor. We found that the copy number differences between PT and PDX are no greater than the variations among 506 multi-region tumor samples or intra-patient samples. Thus concerns about the genetic stability of 507 the PDX system are likely to be less important than the spatial heterogeneity of solid tumors 508 themselves. This result is consistent with our results on lineage effects during passaging, which 509 indicate that intratumoral spatial evolution is the major reason for genetic drift.
510
We observed no evidence for systematic mouse environment-induced selection for cancer 511 or treatment-related genes via copy number changes, though individual cases vary (see example 512 in Supplementary Fig. 75 ). Moreover, only a small fraction of sample pairs (2.44%, 43 out of 1758) 513 shows large CNA discordance (see METHODS), suggesting that clonal selection out of a complex 514 population is rare. These results indicate that the variations observed in PDXs are mainly due to 515 spontaneous intratumoral evolution rather than murine pressures. The extreme cases (see 
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72
Agilent SureSelectXT Human All Exon V6+COSMIC or Agilent Human All Exon 50Mb library 73 preparation protocols were used with inputs of 100-3000ng sheared genomic DNA (Covaris).
74
Library construction was performed using the Agilent Technologies SureSelectXT Reagent Kit.
75
The concentration of the amplified library was measured using a Qubit dsDNA HS Assay Kit group the tumor types/subtypes under broader terms as shown in Fig.1 and Supplementary Table   252 2. corresponding tumor grafts at different passages were mapped to the reference human genome (http://heim.ifi.uio.no/bioinf/Projects/CGHExplorer/). CGH-PCF analysis was carried out to call 341 copy number according to parameters previously reported 38 : least allowed deviation = 0.25; least 342 allowed aberration size = 30; winsorize at quantile = 0.001; penalty = 12; threshold = 0.01.
344
Filtering and gene annotation of copy number segments
